PDOs or ex vivo tumor tissue cultures? Choosing the right preclinical model

Which model best fits your translational research - patient-derived organoids or ex vivo tumor tissue cultures?
See how each approach compares on tumor microenvironment preservation, scalability, reproducibility, and study duration.

Download the on-demand webinar for practical guidance on choosing and establishing the right model for your workflow.

Discover how our cancer culture solutions can support both PDO and tumor tissue culture research.

Key takeaways from the webinar:

• How PDOs and tumor slice cultures differ in tumor microenvironment preservation, scalability, reproducibility, and experimental timescale
• Where each model offers advantages for drug screening, immunotherapy research, and other translational applications
• Key practical considerations when establishing and maintaining PDO and tumor tissue culture workflows
• How tumor slice cultures and PDOs can be used as complementary models to generate insights from the same patient material